Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
Eli Lilly's highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday.